Bisoprolol Vitabalans

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Bisoprolol Vitabalans

Property Description
Active ingredient Bisoprolol Fumarate
Form Oral Tablet
Pharmacological class Cardioselective Beta-Blocker
General purpose Reduces heart rate and workload
Origin Synthetic

Bisoprolol Vitabalans is a prescription-only medicine (Rx) containing the active substance Bisoprolol Fumarate, which is primarily categorized as a cardioselective beta-blocker.


What Type of Medicine is Bisoprolol Vitabalans?

Bisoprolol Vitabalans is part of the class of beta-adrenergic antagonists, commonly known as beta-blockers. The active ingredient, Bisoprolol Fumarate (INN), is a synthetic compound that is medically recognized for its highly selective action on the beta-1 receptors predominantly located in the heart. This targeted approach is intended to reduce potential unwanted effects on other receptors in the body, such as those that control the airways, compared to non-selective agents. The selective nature of the drug means its main action is focused on controlling the heart.


Composition and Form: What is in the Tablet?

This medication is formulated as an oral tablet and contains Bisoprolol Fumarate as its single active ingredient. This preparation is intended for oral administration (swallowing) and is a single-agent composition, which is typical for initial treatment phases and simplifies dose adjustment. The tablets include non-active components, or excipients, that facilitate tablet formation and ensure proper delivery of the synthetic Bisoprolol Fumarate upon ingestion.


General Purpose: What Does a Selective Beta-Blocker Do?

The overall purpose of Bisoprolol Vitabalans is to promote more efficient heart function by decreasing the heart's rate and force of contraction. By blocking the effects of stimulating hormones like adrenaline on the heart muscle, the drug essentially slows the pace. This therapeutic effect allows the heart to rest and requires less oxygen, thereby reducing the stress placed on the heart muscle over time. This action results in the heart beating more steadily and with less effort, which is fundamental to cardiovascular support.

What side effects are possible with Bisoprolol Vitabalans?

Possible Side Effects and Safety Information

This section summarizes the officially documented adverse reactions and safety characteristics of Bisoprolol Fumarate, organized by frequency and affected physiological systems, as defined in regulatory labeling.


Frequency-Classified Adverse Reactions

The safety profile is categorized based on reported frequency in clinical data, affecting various System-Organ Classes (SOCs):

  • Very Common (may affect more than 1 in 10 patients): Marked slowing of the heart rate (bradycardia), particularly noted in chronic heart failure patients.
  • Common (may affect up to 1 in 10 patients): Fatigue and asthenia; dizziness and headache; gastrointestinal disturbances like nausea, vomiting, diarrhoea, and constipation; hypotension (low blood pressure); and a sensation of coldness or numbness in the extremities.
  • Uncommon (may affect up to 1 in 100 patients): Sleep disorders, depression, disturbances in heart conduction (AV-conduction disturbances), and muscular weakness.

Time-Related Patterns and Safety Constraints

Official labeling documents specific patterns and restrictions for use:

  1. Time-Related Effects: The common effects, such as fatigue and dizziness, are most likely to occur at the beginning of therapy for hypertension or angina, often resolving within the first one to two weeks. Transient worsening of heart failure may also occur during the dose titration period.
  2. Abrupt Cessation Risk: The medicine must not be stopped abruptly, especially in individuals with coronary artery disease, due to the regulatory-documented risk of exacerbation of angina pectoris, myocardial infarction, or severe arrhythmia.
  3. Special Populations: The use of Bisoprolol Fumarate is not recommended in the pediatric population due to insufficient data. Specific dose restrictions (not to exceed 10 mg daily) apply in cases of severe renal or hepatic impairment.
  4. Contraindications: Use is restricted in patients with conditions like acute heart failure, cardiogenic shock, severe marked sinus bradycardia, or certain high-degree AV heart blocks (without a pacemaker), as explicitly defined in the prescribing information.

Overdose and Emergency Response

Overdose involving Bisoprolol Vitabalans is primarily associated with an exaggeration of its established cardiovascular effects. The officially documented clinical manifestations of overdose include profound bradycardia (abnormally slow heart rate) and significant hypotension (abnormally low blood pressure). These manifestations reflect the excessive pharmacological actions of the cardioselective beta-blocker on the heart.

Should an overdose occur, the regulatory guidelines require that Bisoprolol fumarate therapy should be stopped immediately. Patients experiencing signs such as excessive bradycardia or marked low blood pressure are advised to consult a physician for urgent medical attention.

The management described in regulatory prescribing information focuses on providing supportive and symptomatic treatment. Procedures may involve the administration of sympathomimetic agents in some reported cases to counteract the effects of severe beta-blockade. Management strategies are aligned with established recommendations for managing overdose by beta-blocking agents. Furthermore, limited data are available regarding clearance; however, Bisoprolol fumarate is generally considered not dialyzable as an effective means of removal. Reported cases of overdose, involving doses up to 2000 mg, resulted in recovery for all patients documented in the prescribing information.

Therapeutic Uses of Bisoprolol Vitabalans

What Bisoprolol Vitabalans Treats: Main Uses and Benefits

Bisoprolol Vitabalans is commonly used across conditions presenting with systemic or localized discomfort, generally helping to address symptoms that create noticeable physiological strain.

The medication is commonly used in the management of high blood pressure (hypertension), chronic stable angina pectoris, and stable chronic heart failure.

In these contexts, the medication primarily helps address symptom clusters that may become intense or disruptive, such as recurrent chest discomfort and pain, and symptoms that interfere with daily functioning. This therapeutic approach generally contributes to maintaining functional stability and may help patients cope more steadily with symptom fluctuations and instability. For patients with these chronic conditions, it provides support that helps ease the overall symptom burden and stability.

Quick Fact: Supportive Symptom Management
Bisoprolol is relevant for easing symptoms related to systemic imbalance, providing supportive relief when symptoms interfere with routine activities.

Regulatory References

  1. Bisoprolol: MedlinePlus Drug Information

Eligibility and Restrictions for Use

Official Eligibility and Contraindications

Bisoprolol Vitabalans is approved for use in adults (18 years and over) for managing hypertension, angina pectoris, and stable chronic heart failure. Older adults typically require no routine dosage adjustment.

Contraindicated Populations: The medicine is explicitly contraindicated for patients with hypersensitivity to the drug or excipients, acute heart failure or cardiac decompensation, cardiogenic shock, or severe cardiac conduction defects such as second- or third-degree AV block or symptomatic bradycardia. It must also not be used in cases of severe bronchial asthma or severe COPD, untreated phaeochromocytoma, or metabolic acidosis.

Restricted and Conditional Use: Use is not recommended for children and adolescents (under 18 years) due to a lack of established safety and efficacy data. Patients with severe renal or hepatic impairment have a regulatory-labeled dose limit that must not be exceeded. Caution is also mandated for patients with diabetes mellitus (due to potential masking of hypoglycemia symptoms) and those with psoriasis (requiring careful benefit-risk assessment).

Pregnancy and Lactation: Use during pregnancy is permitted only if clearly needed. Use while breastfeeding is generally not recommended for newborns.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The official regulatory profile for Bisoprolol Fumarate identifies specific combinations that are restricted or require careful administration due to documented interaction patterns.

Contraindicated and Restricted Combinations

Co-administration with other beta-blocking agents is generally not recommended, as is use with calcium antagonists of the verapamil or diltiazem type, due to the additive negative influence on cardiac function and AV conduction. Similarly, centrally acting antihypertensive drugs (including clonidine and methyldopa) are restricted combinations due to the risk of worsening heart failure. MAOIs (excluding MAO-B inhibitors) are typically prohibited due to the risk of an enhanced hypotensive effect.


Pharmacokinetic and Timing Rules

Certain substances alter the exposure of Bisoprolol. Rifampin is documented to increase the metabolic clearance of the drug, which shortens its elimination half-life. Conversely, products containing aluminum hydroxide or a multivitamin with minerals may decrease Bisoprolol's effectiveness by inhibiting its absorption; administration of these products must be separated by at least two hours.


Pharmacodynamic Cautions

The blood pressure-lowering effect may be reduced when co-administered with Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). For individuals taking insulin or oral antidiabetic agents, Bisoprolol may enhance the blood-sugar-lowering effect and can mask the typical symptoms of hypoglycemia. Alcohol also adds to the overall blood pressure lowering effect. Caution is noted for patients with significant renal or hepatic dysfunction, as decreased drug clearance may increase the risk of adverse effects from combinations.

Mechanism of Action

Bisoprolol Fumarate, the active ingredient, operates as a competitive antagonist primarily targeting the Beta-1 (beta1) Adrenoceptors predominantly located in the heart. .

By binding to these sites, Bisoprolol Fumarate prevents the stimulating effects of circulating catecholamines (norepinephrine and epinephrine) from initiating the cell signaling cascade. This suppression of the sympathetic drive leads to a reduction in intracellular chemical activity, specifically cyclic AMP and calcium ion ( Ca^2+) influx, which mediates cardiac chronotropy and inotropy.

The molecular blockade translates into two direct physiological consequences: negative chronotropy (slowing the heart rate) and negative inotropy (reducing the force of contraction). Negative chronotropy is due to a reduced firing rate of the heart's pacemaker (Sinoatrial node), while negative inotropy affects the strength of myocardial contraction. This combined effect lowers the heart's cardiac output and decreases its myocardial oxygen demand.

The mechanism also influences the kidneys by blocking beta1 receptors on the juxtaglomerular cells. This causes a suppression of the release of renin, the enzyme that initiates the Renin-Angiotensin-Aldosterone System (RAAS), contributing to an alteration in systemic vascular resistance and circulatory dynamics.

Dosage and Administration Information

Instruction Map: How to use Bisoprolol Vitabalans — Administration Guidelines

Category Instruction
Route of administration Oral administration only, via film-coated tablets.
Timing in relation to meals The tablets may be taken with or without food as the medicine's absorption is not significantly affected by food intake.
Preparation requirements The tablet should be swallowed whole with liquid, and certain strengths are scored to facilitate division for dosing accuracy.
Missed-dose rules If a dose is missed, the next scheduled dose is taken at the usual time, and a double dose should not be taken to compensate.

Dosing Schedule

The medicine is taken once daily, often in the morning, though the specific dose depends on the condition being addressed:

  • Hypertension and Angina: The typical starting dose is 5 mg once daily, with the option to increase to a maximum recommended dose of 20 mg once daily.
  • Chronic Heart Failure (CHF): Treatment requires initiation with a low dose of 1.25 mg once daily. The dose is then subject to a gradual, step-wise increase (titration) over several weeks, not to exceed the maximum recommended dose of 10 mg once daily.

Population-Specific and Procedural Conditions

The initial daily dose is reduced to 2.5 mg for patients with significant hepatic or renal impairment.

Treatment is typically long-term, and discontinuation must not be abrupt; the dose is gradually reduced over approximately one week to manage the cessation of therapy.


Connection to the overall use protocol: The protocol establishes a standardized oral, once-daily pattern where the administered dose is defined by the treated condition and adjusted for patients with reduced organ function. This protocol involves specific, controlled titration and tapering sequences, defining the time, amount, and manner in which the medicine is to be ingested over the full course of long-term therapy.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Bisoprolol Vitabalans

The evidence for Bisoprolol Fumarate has been collected over many years through structured studies, including large-scale randomized controlled trials (RCTs). These studies form the research background and describe the health outcomes observed in the study populations for the conditions examined. The following summary outlines the types of research conducted and the areas where data are most and least established, using neutral language only.

Evidence for Use in Chronic Heart Failure

Research for chronic heart failure primarily involves large, multi-center Randomized Controlled Trials (RCTs). These studies were designed to assess what happens when the medicine is added to the existing standard care for patients diagnosed with stable chronic heart failure and reduced left ventricular function. Studies report patterns where all-cause mortality and cardiovascular death were observed in fewer participants compared to control groups. Reports described hospitalization for worsening heart failure was observed in fewer participants across several major trials when compared to control groups. Findings were synthesized in multiple peer-reviewed scientific reviews and government-linked sources.

Evidence for Use in Managing High Blood Pressure (Hypertension)

Studies for the management of high blood pressure typically involve randomized, controlled trials where the medicine was evaluated against an inactive substance (placebo) or against other antihypertensive agents. The main focus of these research efforts was to measure the change in systemic blood pressure and heart rate over defined time intervals. Trials reported measurements that were lower for systolic and diastolic blood pressure compared to baseline and to control groups. Research describes measured changes in blood pressure and heart rate, contributing to the broader evidence landscape for this condition.

Evidence for Use in Chronic Stable Angina Pectoris

The research for chronic stable angina pectoris has explored the use of the medicine in patients experiencing chest discomfort. The primary outcomes examined in these studies included functional measures, such as exercise capacity, and patient-reported outcomes describing symptom patterns. Studies describe patterns where the frequency of angina episodes and the usage of relief medication were reduced, and where measurements of exercise tolerance showed positive changes in the cohorts studied.

Duration of Studies and Long-Term Follow-up

For chronic heart failure, the core RCTs typically utilized long-term follow-up, with many trials extending well beyond one year. Data for long-term outcomes remains limited regarding the sustained blood pressure control over many years and the long-term patterns related to major cardiovascular event rates in uncomplicated hypertension.

Frequently Asked Questions (FAQ)

Common questions about Bisoprolol Vitabalans (FAQ)


Q: How long does it typically take for Bisoprolol Vitabalans to start working?

Official information indicates that the active ingredient begins to show an effect on heart rate within a few hours. Regulatory documents note that the maximal effect on slowing the heart rate typically occurs within one to four hours after taking a single dose.

Q: Can Bisoprolol Vitabalans be split in half?

Regulatory information specifies that certain tablet strengths are scored. These scored tablets are designed to be divided to facilitate an accurate dose.

Q: What happens if a dose of Bisoprolol Vitabalans is missed?

Official instructions advise against taking a double dose to compensate for a missed dose. Regulatory information suggests the next dose should be taken at the usual scheduled time.

Q: How is Bisoprolol Vitabalans generally stopped or discontinued?

Official protocols state that the medicine should not be stopped suddenly. Abrupt withdrawal carries a documented risk, especially for individuals with coronary artery disease, and may lead to a worsening of symptoms like angina or heart rhythm problems.

Q: Can Bisoprolol Vitabalans be taken on an empty stomach?

Studies on how the medicine is absorbed into the body show that its effectiveness is not significantly altered by food intake. Therefore, official documents state it can be taken with or without food.

Q: What should be done if someone accidentally takes too much Bisoprolol Vitabalans?

Official patient information states that immediate emergency medical assistance should be sought if an overdose is suspected. Symptoms of an overdose may include a very slow heart rate, severe difficulty breathing, extreme dizziness, or signs of low blood sugar.

Q: Is Bisoprolol Vitabalans a safe drug for long-term use?

Treatment for approved conditions is supported by long-term clinical trials. Regulatory documents describe treatment for conditions such as stable chronic heart failure as generally being a long-term course.

Q: Can Bisoprolol Vitabalans be taken with supplements or vitamins?

Official documents caution that detailed information regarding combining the medicine with all herbal remedies or supplements is often limited. Regulatory information suggests informing a healthcare professional about all products, including supplements and vitamins, that are being used.

Q: How long does Bisoprolol Vitabalans stay in the system?

The drug is documented to have an elimination half-life—the time it takes for half of the dose to be cleared from the bloodstream—of approximately 9 to 12 hours. This duration helps support a consistent 24-hour effect with once-daily dosing.

Q: Can Bisoprolol Vitabalans be taken with high-dose vitamin D?

Regulatory information advises informing a healthcare professional about all supplements taken, but official sources do not uniformly document a specific caution or required separation for high-dose Vitamin D itself.

Q: How is Bisoprolol Vitabalans different from metoprolol?

The active ingredient is officially classified as a highly selective beta-1 adrenoceptor blocking agent. This classification refers to its targeted action, meaning it primarily affects the beta-1 receptors in the heart, which describes its difference from medicines that may be less selective.

Q: Does the time of day Bisoprolol Vitabalans is taken matter?

Official guidelines instruct that the tablets should be taken once daily. Regulatory documents recommend taking the dose in the morning to maintain consistent medication levels throughout the 24-hour period.

Q: What research exists about Bisoprolol Vitabalans in children?

Official regulatory sources state there is no established pediatric experience with the drug. For this reason, its use is not recommended for children and adolescents due to insufficient data on safety and efficacy in these age groups.

Q: Does Bisoprolol Vitabalans cause swelling in the legs or ankles?

Some regulatory documents list edema, which is swelling, as a reported adverse effect. Swelling is sometimes reported as a general reaction to medicines in this class.

Q: Is Bisoprolol Vitabalans linked to weight changes?

Weight gain is listed as a reported adverse effect in the general adverse reaction sections of some official documentation.

Q: Does Bisoprolol Vitabalans have a risk of causing a cough?

Coughing is listed as a reported adverse reaction in regulatory documents, categorized under the respiratory system organ class.

Q: Can Bisoprolol Vitabalans lead to vision changes?

Official labeling lists visual disturbances and abnormal lacrimation (reduced tear flow) as reported adverse reactions affecting the special senses.

Q: What is the official recommended storage condition for Bisoprolol Vitabalans tablets?

Official requirements state the medicine should be kept in its original packaging and protected from moisture. Like all medicines, it must be stored securely out of the sight and reach of children.

Q: How common is hair loss as a side effect of Bisoprolol Vitabalans?

Alopecia, the medical term for hair loss, is listed as a reported adverse effect in the regulatory documentation under the classification of skin reactions.

Q: Does Bisoprolol Vitabalans cause problems with male sexual function?

Official labeling lists decreased libido and impotence as documented adverse effects under the genitourinary system.

Q: Are there any official reports of Bisoprolol Vitabalans interactions with common cold or flu medicines?

Official documents caution against co-administration with sympathomimetic agents. These are ingredients often found in common cold or flu medicines, and combining them with the drug carries a potential risk of an additive effect, such as increasing blood pressure.

Q: Do any studies discuss the effect of Bisoprolol Vitabalans on kidney function?

Pharmacokinetic data shows that the medicine is eliminated through both the kidneys and the liver. Regulatory information notes that the rate of elimination is slower in patients who have pre-existing renal impairment, which is why a reduced dose may be required for these patients.

How should Bisoprolol Vitabalans be stored and disposed of?

How to Store and Dispose of Bisoprolol Vitabalans?

The storage and disposal instructions for Bisoprolol Vitabalans are defined by regulatory labeling to ensure product stability and environmental safety.

Official Storage Requirements

Storage Factor Labeled Requirement
Temperature No special temperature conditions are required.
Protection Store in a dry place and protect the tablets from moisture.
Container The medicine must be kept in its original container.
Stability Do not use the tablets after the expiry date indicated on the packaging.
Child Safety The medicine must be kept securely out of the sight and reach of children.

Disposal Instructions

To dispose of Bisoprolol Vitabalans, unused or expired medicine must be returned to a pharmacist or pharmaceutical waste collection point. Disposal must be carried out in accordance with local regulatory requirements. The medicine must not be thrown away into wastewater (e.g., flushed down the toilet or sink) to prevent environmental contamination.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Bisoprolol Vitabalans found in:

A-Z Index: